NCT02177266View on ClinicalTrials.gov

Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation

PHASE3TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Atrial FibrillationPost-pericardiotomy SyndromeConstriction
Interventions
DRUG

Colchicine

Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.

DRUG

Placebo

The placebo will match the study drug.

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT02177266 - Colchicine to Prevent Post-Pericardiotomy Syndrome and Atrial Fibrillation | Biotech Hunter | Biotech Hunter